Mitch Dowsett

List of Publications by Year
in descending order

163 papers	26,083 citations	18436 62 h-index	6630 156 g-index
167 all docs	167 docs citations	167 times ranked	22428 citing authors

#	Article	IF	Citations
1	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â'' Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	3.2	8
2	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. Cancer Research, 2022, 82, PD2-07-PD2-07.	0.4	0
3	Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6 Cancer Research, 2022, 82, PD15-03-PD15-03.	0.4	0
4	Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. Cancer Research, 2022, 82, PD14-08-PD14-08.	0.4	1
5	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. European Journal of Cancer, 2022, 164, 52-61.	1.3	0
6	Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptorâ€"positive Breast Cancers. Clinical Cancer Research, 2022, 28, 1217-1228.	3.2	6
7	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	5.1	4
8	Breast Cancer Prevention Is Better Than Cure. JCO Oncology Practice, 2022, , OP2200002.	1.4	1
9	Testing Endocrine Response for Managing Primary Estrogen Receptorâ€"Positive Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2520-2523.	0.8	6
10	Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer. Endocrine-Related Cancer, 2022, 29, R105-R122.	1.6	17
11	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	2.9	18
12	Ki67 as a Companion Diagnostic: Good or Bad News?. Journal of Clinical Oncology, 2022, 40, 3796-3799.	0.8	10
13	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2021, 186, 115-123.	1.1	12
14	Calibration of CTS5 in Women With Early Estrogen Receptorâ€"Positive Breast Cancer. Journal of Clinical Oncology, 2021, 39, 338-339.	0.8	3
15	Molecular Drivers of Onco<i>type</i> DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Journal of Clinical Oncology, 2021, 39, 126-135.	0.8	69
16	Development and validation for research assessment of Oncotype DXÂ® Breast Recurrence Score, EndoPredictÂ® and ProsignaÂ®. Npj Breast Cancer, 2021, 7, 15.	2.3	11
17	A simple digital image analysis system for automated Ki67 assessment in primary breast cancer. Histopathology, 2021, 79, 200-209.	1.6	9
18	â€œReal-worldâ€•radiomics from multi-vendor MRI: an original retrospective study on the prediction of nodal status and disease survival in breast cancer, as an exemplar to promote discussion of the wider issues. Cancer Imaging, 2021, 21, 37.	1.2	13

#	Article	IF	Citations
19	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment, 2021, 190, 295-305.	1.1	1
20	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819.	3.0	319
21	UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 86-94.	0.6	5
22	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. Breast Cancer Research, 2020, 22, 2.	2.2	15
23	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1443-1454.	5.1	159
24	Evidence-based guidelines for managing patients with primary ER+ HER2ˆ' breast cancer deferred from surgery due to the COVID-19 pandemic. Npj Breast Cancer, 2020, 6, 21.	2.3	42
25	Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene, 2020, 39, 4781-4797.	2.6	52
26	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology, 2019, 32, 59-69.	2.9	78
27	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	1.4	11
28	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. Biomarkers in Cancer, 2019, 11, 1179299X1985151.	3.6	4
29	Reply to J.A. Sparano et al. Journal of Clinical Oncology, 2019, 37, 1842-1842.	0.8	0
30	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports, 2019, 29, 889-903.e10.	2.9	40
31	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€"Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	1.4	15
32	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	1.6	74
33	Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. Breast Cancer Research and Treatment, 2019, 175, 317-326.	1.1	2
34	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptorâ€"Positive Early Breast Cancer: PALLET Trial. Journal of Clinical Oncology, 2019, 37, 178-189.	0.8	136
35	Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. Journal of Clinical Oncology, 2019, 37, 689-692.	0.8	26
36	Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Modern Pathology, 2019, 32, 1244-1256.	2.9	51

#	Article	IF	Citations
37	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research, 2019, 39, 797-802.	0.5	0
38	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. Clinical Cancer Research, 2019, 25, 7485-7496.	3.2	18
39	Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. Npj Breast Cancer, 2019, 5, 42.	2.3	13
40	Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Research, 2019, 21, 135.	2.2	12
41	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nature Reviews Clinical Oncology, 2019, 16, 296-311.	12.5	64
42	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. British Journal of Cancer, 2019, 120, 247-255.	2.9	13
43	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	3.4	246
44	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. Journal of Clinical Oncology, 2018, 36, 1941-1948.	0.8	116
45	Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. JCO Precision Oncology, 2018, 2, 1-12.	1.5	5
46	Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky005.	1.4	11
47	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. Journal of Pathology: Clinical Research, 2018, 4, 262-273.	1.3	43
48	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. Clinical Cancer Research, 2018, 24, 4763-4770.	3.2	30
49	Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. Cancer Prevention Research, 2017, 10, 171-176.	0.7	4
50	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology, 2017, 35, 1041-1048.	0.8	87
51	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, The, 2017, 389, 1195-1205.	6.3	770
52	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Research, 2017, 19, 16.	2.2	83
53	Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. Cancer Causes and Control, 2017, 28, 1441-1452.	0.8	16
54	Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy. Npj Breast Cancer, 2017, 3, 47.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nature Communications, 2017, 8, 1865.	5.8	108
56	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	13.9	1,052
57	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.4	509
58	Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. Clinical Cancer Research, 2016, 22, 2405-2416.	3.2	41
59	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology, 2016, 2, 1040.	3.4	73
60	Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor–Positive Lymph Node–Negative Early-Stage Breast Cancer. Clinical Cancer Research, 2016, 22, 5043-5048.	3.2	18
61	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute, 2016, 108, djw149.	3.0	165
62	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Research and Treatment, 2016, 159, 71-78.	1.1	11
63	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nature Communications, 2016, 7, 13294.	5.8	34
64	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Npj Breast Cancer, 2016, 2, 16014.	2.3	109
65	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	2.2	56
66	Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study. Breast Cancer Research, 2016, 18, 96.	2.2	13
67	Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Research, 2016, 18, 58.	2.2	98
68	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2961-2968.	0.8	573
69	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. Breast Cancer Research, 2016, 18, 39.	2.2	24
70	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	1.6	62
71	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. Cancer Research, 2016, 76, 1615-1626.	0.4	82
72	Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. Journal of Clinical Pathology, 2016, 69, 128-135.	1.0	12

#	Article	IF	Citations
73	High‑throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	1.3	19
74	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1580-1583.	0.8	26
75	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 2763-2770.	3.2	36
76	Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). Clinical Cancer Research, 2015, 21, 2932-2940.	3.2	27
77	AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) *In Vivo*. Molecular Cancer Therapeutics, 2015, 14, 2035-2048.	1.9	55
78	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	2.2	8
79	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	2.9	195
80	Reply to E.A. Rakha et al. Journal of Clinical Oncology, 2015, 33, 1302-1304.	0.8	31
81	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 2015, 7, 302ra133.	5.8	889
82	Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. Breast, 2015, 24, S78-S83.	0.9	22
83	Analysis of *ESR1* mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science Translational Medicine, 2015, 7, 313ra182.	5.8	460
84	Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Research and Treatment, 2015, 149, 1-4.	1.1	57
85	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. Journal of Clinical Oncology, 2015, 33, 916-922.	0.8	189
86	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 1460-1468.	5.1	56
87	Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor‑Positive Breast Cancer and Their Relationship with Antiproliferative Response. Clinical Cancer Research, 2014, 20, 2485-2494.	3.2	39
88	Reply to R. Bhargava et al and K. Lambein et al. Journal of Clinical Oncology, 2014, 32, 1857-1859.	0.8	3
89	Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 3962-3973.	3.2	19
90	Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. European Journal of Cancer, 2014, 50, 1055-1064.	1.3	35

#	ARTICLE	IF	CITATIONS
91	Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 327-335.	1.1	24
92	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). Journal of Clinical Oncology, 2014, 32, 2159-2165.	0.8	207
93	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Modern Pathology, 2014, 27, 4-18.	2.9	236
94	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
95	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncology, The, 2013, 14, 1067-1076.	5.1	332
96	An International Ki67 Reproducibility Study. Journal of the National Cancer Institute, 2013, 105, 1897-1906.	3.0	498
97	Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2783-2790.	0.8	557
98	Sex hormones and breast cancer risk and prognosis. Breast, 2013, 22, S38-S43.	0.9	84
99	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
100	Biomarkers for the clinical management of breast cancer: International perspective. International Journal of Cancer, 2013, 133, 1-13.	2.3	144
101	Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment, 2013, 138, 157-165.	1.1	37
102	Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance. Clinical Cancer Research, 2013, 19, 2775-2786.	3.2	119
103	GDNF–RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors. Cancer Research, 2013, 73, 3783-3795.	0.4	97
104	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Research, 2012, 14, R57.	2.2	75
105	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2012, 133, 1191-1198.	1.1	36
106	The role of caveolin-1 in human breast cancer. Breast Cancer Research and Treatment, 2012, 131, 1-15.	1.1	63
107	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4273-4278.	0.8	666
108	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2011, 103, 1656-1664.	3.0	1,505

#	Article	IF	Citations
109	Predictive algorithms for adjuvant therapy: TransATAC. Steroids, 2011, 76, 777-780.	0.8	32
110	ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer Discovery, 2011, 1, 338-351.	7.7	284
111	Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors. Journal of Clinical Oncology, 2011, 29, 4365-4372.	0.8	123
112	Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 120-123.	0.9	69
113	Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Research and Treatment, 2010, 123, 829-836.	1.1	37
114	Comparative validation of the SP6 antibody to Ki67 in breast cancer. Journal of Clinical Pathology, 2010, 63, 800-804.	1.0	59
115	Reply to M. Rosman et al. Journal of Clinical Oncology, 2010, 28, e648-e648.	0.8	1
116	Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology, 2010, 28, 1161-1167.	0.8	94
117	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 2010, 28, 1829-1834.	0.8	647
118	Reply to B. Seruga et al. Journal of Clinical Oncology, 2010, 28, e348-e348.	0.8	0
119	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology, 2010, 28, 509-518.	0.8	716
120	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology, The, 2010, 11, 1135-1141.	5.1	1,017
121	Predictive and prognostic factors. Breast Cancer Research, 2010, 12, S2.	2.2	3
122	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	1.2	697
123	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	1.2	855
124	Disease-Free Survival According to Degree of *HER2* Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. Journal of Clinical Oncology, 2009, 27, 2962-2969.	0.8	164
125	The potential of new technologies/approaches. Introduction to Sessions 3 and 4. Breast Cancer Research, 2009, 11, S9.	2.2	0
126	Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast Cancer Research, 2009, 11, S15.	2.2	18

#	ARTICLE	IF	CITATIONS
127	Optimizing the implementation of future treatment using surrogate end-points. Breast Cancer Research, 2008, 10, S26.	2.2	5
128	Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clinical Cancer Research, 2008, 14, 8019-8026.	3.2	220
129	Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 2008, 26, 1059-1065.	0.8	409
130	Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics. Journal of the National Cancer Institute, 2008, 100, 1380-1388.	3.0	566
131	Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 167-170.	3.0	608
132	HER2 testing in the UK: consensus from a national consultation. Journal of Clinical Pathology, 2007, 60, 685-689.	1.0	31
133	Influences on circulating oestrogens in postmenopausal women: Relationship with breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 99-109.	1.2	59
134	International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Research, 2007, 9, R81.	2.2	86
135	Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology, 2007, 20, 584-591.	2.9	119
136	Comparison of Methods to Measure Low Serum Estradiol Levels in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3791-3797.	1.8	175
137	Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer. Clinical Cancer Research, 2006, 12, 1024s-1030s.	3.2	105
138	Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole. Journal of Clinical Oncology, 2006, 24, 3019-3025.	0.8	170
139	The biology of steroid hormones and endocrine treatment of breast cancer. Breast, 2005, 14, 452-457.	0.9	41
140	Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Research and Treatment, 2005, 93, 11-18.	1.1	70
141	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists. Journal of Clinical Oncology, 2005, 23, 2477-2492.	0.8	263
142	Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study. Journal of Clinical Oncology, 2005, 23, 7512-7517.	0.8	248
143	Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial. Journal of Clinical Oncology, 2005, 23, 5108-5116.	0.8	693
144	Mechanisms of resistance to aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 167-172.	1.2	51

#	Article	IF	Citations
145	Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research, 2005, 11, 951s-8s.	3.2	195
146	Translational research and the changing face of breast cancer. Breast Cancer Research and Treatment, 2004, 87, 1-2.	1.1	21
147	Biomarker investigations from the ATAC trial: the role of TA01. Breast Cancer Research and Treatment, 2004, 87, 11-18.	1.1	13
148	Designing the future shape of breast cancer diagnosis, prognosis and treatment. Breast Cancer Research and Treatment, 2004, 87, 27-29.	1.1	4
149	Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Research, 2004, 7, 1-4.	2.2	68
150	Efforts to link biological and clinical breast cancer research. Breast, 2003, 12, 442-446.	0.9	2
151	Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Seminars in Oncology, 2003, 30, 58-69.	0.8	49
152	New biology of the oestrogen receptor. Lancet, The, 2003, 362, 260-262.	6.3	16
153	Aromatase Inhibitors in Breast Cancer. New England Journal of Medicine, 2003, 348, 2431-2442.	13.9	826
154	Preoperative models to evaluate endocrine strategies for breast cancer. Clinical Cancer Research, 2003, 9, 502S-10S.	3.2	21
155	Breast cancer: Aromatase inhibitors take on tamoxifen. Nature Medicine, 2002, 8, 1341-1344.	15.2	30
156	Measurement of markers for breast cancer in a model system using laser scanning cytometry. Cytometry, 2000, 41, 166-171.	1.8	16
157	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. , 1999, 85, 1996-2000.		27
158	Clinical Pharmacology of Selective Estrogen Receptor Modulators. Drugs and Aging, 1999, 14, 323-336.	1.3	28
159	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. , 1999, 85, 1996.		1
160	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer, 1999, 85, 1996-2000.	2.0	62
161	Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment, 1998, 49, S53-S57.	1.1	16
162	Effects of 4-Hydroxyandrost-4-Ene-3,17-Dione and Its Metabolites on 5α-Reductase Activity and the Androgen Receptor. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 141-147.	0.5	9

#	Article	IF	Citations
163	Comparison of Aromatase Activity in Human Prostatic, Testicular and Placental Tissues. Journal of Enzyme Inhibition and Medicinal Chemistry, 1991, 4, 307-313.	0.5	10